Vatiquinone

Phase 2/3Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mitochondrial Diseases

Conditions

Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome

Trial Timeline

Sep 28, 2020 → Dec 27, 2023

NCT ID

NCT04378075

About Vatiquinone

Vatiquinone is a phase 2/3 stage product being developed by PTC Therapeutics for Mitochondrial Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT04378075. Target conditions include Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease.

What happened to similar drugs?

0 of 1 similar drugs in Mitochondrial Diseases were approved

Approved (0) Terminated (0) Active (1)

🔄VatiquinonePTC TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07159139	Pre-clinical	Active	—	—	Mitochondrial Disease
NCT05515536	Phase 3	Active	Dec 8, 2022	Dec 31, 2027	Friedreich Ataxia
NCT05485987	Phase 2	Completed	Oct 12, 2022	Aug 29, 2024	Friedreich Ataxia
NCT05218655	Phase 3	Completed	Jun 22, 2022	Apr 15, 2025	Inherited Mitochondrial Disease
NCT04378075	Phase 2/3	Terminated	Sep 28, 2020	Dec 27, 2023	Mitochondrial Diseases

Competing Products

13 competing products in Mitochondrial Diseases

See all competitors

Product	Company	Stage	Hype Score
REN001	OnKure Therapeutics	Phase 1	11
Mavodelpar + Placebo	OnKure Therapeutics	Phase 2	25
REN001	OnKure Therapeutics	Phase 2/3	20
Bocidelpar + Placebo	Astellas Pharma	Phase 2	27
Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mg	AbbVie	Phase 2	35
Cysteamine Bitartrate	Amgen	Phase 2	27
Cysteamine Bitartrate	Amgen	Phase 2	35
EPI-743	PTC Therapeutics	Pre-clinical	23
RG2133 (2',3',5'-tri-O-acetyluridine)	Repligen	Phase 1	18
Vatiquinone	PTC Therapeutics	Pre-clinical	27
Vatiquinone	PTC Therapeutics	Phase 3	37
Oral administration of 100 mg KH176 twice daily	Certara	Phase 2	29
Sonlicromanol + Placebo	Certara	Phase 2	33